PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very...

60

Transcript of PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very...

Page 1: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved
Page 2: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

1

Page 3: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

2

Page 4: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

3

Page 5: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

4

Page 6: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

5

Page 7: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

6

Page 8: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

7

Page 9: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

8

Page 10: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

9

Page 11: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

10

Page 12: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

11

Page 13: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

12

Page 14: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved
Page 15: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

13

Page 16: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

14

Page 17: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

15

Page 18: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

16

Page 19: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

17

Page 20: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

18

Page 21: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

19

Page 22: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

20

Page 23: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved
Page 24: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

21

Page 25: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

22

Page 26: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

23

Page 27: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

24

Page 28: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

25

Page 29: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

26

Page 30: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

27

Page 31: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

28

Page 32: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

29

Page 33: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved
Page 34: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

30

Page 35: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

31

Page 36: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

32

Page 37: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

33

Page 38: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

34

Page 39: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved
Page 40: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

35

Page 41: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

36

Page 42: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

37

Page 43: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

38

Page 44: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

39

Page 45: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

40

Page 46: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

41

Page 47: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved
Page 48: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

42

Page 49: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

43

Page 50: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

44

Page 51: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

45

Page 52: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

1

Page 53: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

46

Page 54: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

47

Page 55: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

48

Page 56: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

49

Page 57: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

50

Page 58: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved
Page 59: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

51

Page 60: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

52


Acute Leukemia and the FLT3 Receptor

Acute Leukemia and the FLT3 Receptor

Francisco Estrada Alvarez R1 Medicina Interna CAULE · trasudado exudado proteinas lp/s < 0.5 ldh lp/s < 0.6 ldh lp < 2/3 ldh s ( 0.5 ldh lp/s

Francisco Estrada Alvarez R1 Medicina Interna CAULE · trasudado exudado proteinas lp/s < 0.5 ldh lp/s < 0.6 ldh lp < 2/3 ldh s ( 0.5 ldh lp/s

2020davaonc.com/wp-content/uploads/2019/12/2020GLOB_Heme...17:30 What is Next for the Treatment of Multiple Myeloma 17:45 Future of FLT3 Treatment in AML 18:00 Resistance to BCL2 Inhibitors

2020davaonc.com/wp-content/uploads/2019/12/2020GLOB_Heme...17:30 What is Next for the Treatment of Multiple Myeloma 17:45 Future of FLT3 Treatment in AML 18:00 Resistance to BCL2 Inhibitors

Hemispatial Neglect LDH

Hemispatial Neglect LDH

All patients with FLT3 mutant AML should receive ... · AML should receive midostaurin-based induction therapy: of course ... MPD in murine model. Mutant ... (31.7-NE); PBO 25.6 (18.6-42.9)

All patients with FLT3 mutant AML should receive ... · AML should receive midostaurin-based induction therapy: of course ... MPD in murine model. Mutant ... (31.7-NE); PBO 25.6 (18.6-42.9)

Research Article Mutation of NPM1 and FLT3 Genes in ...downloads.hindawi.com/journals/dm/2013/582569.pdfmechanism of leukemogenesis. 1. Introduction Acute myeloid leukemia (AML) develops

Research Article Mutation of NPM1 and FLT3 Genes in ...downloads.hindawi.com/journals/dm/2013/582569.pdfmechanism of leukemogenesis. 1. Introduction Acute myeloid leukemia (AML) develops

MANUAL: LDH VALVED APPLIANCES

MANUAL: LDH VALVED APPLIANCES

エアツール コンプレッサ - Kyosei Rentemu Co Ltd...φ50〜65 （5ピッチ） 商品コード LGF 04500 LGG 07000 LGF 09000 LDH 20002 LDH 15002 LDH 20002 LDH 30002 メーカー

エアツール コンプレッサ - Kyosei Rentemu Co Ltd...φ50〜65 （5ピッチ） 商品コード LGF 04500 LGG 07000 LGF 09000 LDH 20002 LDH 15002 LDH 20002 LDH 30002 メーカー

LDH Marketing Charity Brochure

LDH Marketing Charity Brochure

Acute Leukemia From Precision Medicine to ImmunoRx · And, Suddenly in 2017 to 2018, FDA Approvals…. •Midostaurin ( RYDAPT®) for de novo younger AML (< or = 60 yrs), FLT3 mutation

Acute Leukemia From Precision Medicine to ImmunoRx · And, Suddenly in 2017 to 2018, FDA Approvals…. •Midostaurin ( RYDAPT®) for de novo younger AML (< or = 60 yrs), FLT3 mutation

Acute Leukemia - prIME Oncology...Prognostic Impact of NPM1/FLT3-ITD Genotypes From Randomized Patients With Acute Myeloid Leukemia (AML) Treated Within the International RATIFY Study

Acute Leukemia - prIME Oncology...Prognostic Impact of NPM1/FLT3-ITD Genotypes From Randomized Patients With Acute Myeloid Leukemia (AML) Treated Within the International RATIFY Study

Adaptation to TKI Treatment Reactivates ERK Signaling in ... · promising therapeutic strategy in patients with FLT3/ITD AML. ... Pediatrics, Johns Hopkins University School of Medicine,

Adaptation to TKI Treatment Reactivates ERK Signaling in ... · promising therapeutic strategy in patients with FLT3/ITD AML. ... Pediatrics, Johns Hopkins University School of Medicine,

FLT3-ITD and NPM1 gene mutations

FLT3-ITD and NPM1 gene mutations

Ldh in Pneumonia (Asrita)

Ldh in Pneumonia (Asrita)

Research Paper Identification of the key genes and ... · therapeutic target for AML [8, 9]. FLT3 inhibitors have approved for clinical use for mutant FLT3-positive AML in Japan and/or

Research Paper Identification of the key genes and ... · therapeutic target for AML [8, 9]. FLT3 inhibitors have approved for clinical use for mutant FLT3-positive AML in Japan and/or

RBC LDH edifice Introduction

RBC LDH edifice Introduction

"FLT3-ITD and FLT3 Inhibitors in the Setting of Allogeneic Stem Cell Transplantation for AML"

"FLT3-ITD and FLT3 Inhibitors in the Setting of Allogeneic Stem Cell Transplantation for AML"

LDH in pneumocystis

LDH in pneumocystis

ImmobilizationofHRPEnzymeonLayeredDoubleHydroxides … · 2019. 7. 31. · LDH + HRP LDH −0.2 (a) 8 6 5 4 3 2 1 0 ×105 LDH + HRP LDH ×105 0 2 4 − Im(Z)(Ω · cm − 2) Re(Z)(Ω·cm−2)

ImmobilizationofHRPEnzymeonLayeredDoubleHydroxides … · 2019. 7. 31. · LDH + HRP LDH −0.2 (a) 8 6 5 4 3 2 1 0 ×105 LDH + HRP LDH ×105 0 2 4 − Im(Z)(Ω · cm − 2) Re(Z)(Ω·cm−2)

LDH Purification

LDH Purification